Company Overview: JNJ

JNJ Overview

Upcoming Projects (JNJ)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (JNJ)

A Third Look: Discussing the topline results from the Phase 3 ICONIC-LEAD Study of icotrokinra (JNJ-2113), an oral peptide targeting the IL-23 receptor, in patients 12 years of age and older with moderate to severe plaque psoriasis.
Ticker: JNJ
Executed On: Dec 11, 2024 at 10:00 AM EST
A Second Look: Discussing the topline results from the Phase 3 ICONIC-LEAD Study of icotrokinra (JNJ-2113), an oral peptide targeting the IL-23 receptor, in patients 12 years of age and older with moderate to severe plaque psoriasis.
Ticker: JNJ
Executed On: Dec 06, 2024 at 12:30 PM EST
Discussing the topline results from the Phase 3 ICONIC-LEAD Study of icotrokinra (JNJ-2113), an oral peptide targeting the IL-23 receptor, in patients 12 years of age and older with moderate to severe plaque psoriasis.
Ticker: JNJ
Executed On: Dec 05, 2024 at 04:00 PM EST
A Third View: Perusing the data from the CARTITUDE-4 clinical trial of Carvykti for multiple myeloma which was presented at the 2024 International Myeloma Society Annual Meeting.
Tickers: LEGN, JNJ
Executed On: Nov 19, 2024 at 11:00 AM EST
A Second Look: Discussing the recent FDA approval of Medtronic's Affera™ Mapping and Ablation System and Boston Scientific's Farawave Nav for Atrial Fibrillation
Tickers: MDT, JNJ, ABT, BSX
Executed On: Nov 15, 2024 at 09:00 AM EST
Discussing the recent FDA approval of Medtronic's Affera™ Mapping and Ablation System and Boston Scientific's Farawave Nav for Atrial Fibrillation
Tickers: MDT, JNJ, ABT, BSX
Executed On: Nov 13, 2024 at 03:30 PM EST
A Second View: Delving into the recent data from the phase 3 GRAVITI and GALAXI clinical trials of Tremfya in patients with Crohn's disease
Tickers: JNJ, LLY
Executed On: Nov 08, 2024 at 03:00 PM EST
A Second View: Perusing the data from the CARTITUDE-4 clinical trial of Carvykti for multiple myeloma which was presented at the 2024 International Myeloma Society Annual Meeting.
Tickers: LEGN, JNJ
Executed On: Nov 05, 2024 at 05:00 PM EST
Perusing the data from the CARTITUDE-4 clinical trial of Carvykti for multiple myeloma which was presented at the 2024 International Myeloma Society Annual Meeting.
Tickers: LEGN, JNJ
Executed On: Nov 01, 2024 at 01:15 PM EDT
Delving into the recent data from the phase 3 GRAVITI and GALAXI clinical trials of Tremfya in patients with Crohn's disease
Tickers: LLY, JNJ
Executed On: Oct 31, 2024 at 05:00 PM EDT
A Second Opinion: Discussing the recent FDA approval of Medtronic's Affera™ Mapping and Ablation System for Atrial Fibrillation
Tickers: MDT, JNJ, ABT, BSX
Executed On: Oct 30, 2024 at 01:00 PM EDT
Discussing the recent FDA approval of Medtronic's Affera™ Mapping and Ablation System for Atrial Fibrillation
Tickers: MDT, JNJ, ABT, BSX
Executed On: Oct 30, 2024 at 08:30 AM EDT
A Third Look: Discussing the current knee and hip replacement landscape based on current brand preferences of orthopedic surgeons.
Tickers: JNJ, SNN, MDT, SYK, ZBH
Executed On: Oct 10, 2024 at 05:00 PM EDT
A Second Look: Discussing the current knee and hip replacement landscape based on current brand preferences of orthopedic surgeons.
Tickers: JNJ, ZBH, SNN, MDT, SYK
Executed On: Oct 08, 2024 at 04:00 PM EDT
A First Look: Discussing the current knee and hip replacement landscape based on current brand preferences of orthopedic surgeons.
Tickers: JNJ, ZBH, SNN, MDT, SYK
Executed On: Oct 08, 2024 at 02:45 PM EDT
Third View: Discussing Johnson & Johnson's Recent Phase 3 QUASAR Results for Treatment of Ulcerative Colitis Through Tremfya.
Ticker: JNJ
Executed On: Sep 19, 2024 at 02:00 PM EDT
Second View: Discussing Johnson & Johnson's Recent Phase 3 QUASAR Results for Treatment of Ulcerative Colitis Through Tremfya.
Ticker: JNJ
Executed On: Sep 17, 2024 at 12:00 PM EDT
Discussing Johnson & Johnson's Recent Phase 3 QUASAR Results for Treatment of Ulcerative Colitis Through Tremfya.
Ticker: JNJ
Executed On: Sep 16, 2024 at 05:00 PM EDT
A Third Look: Discussing the potential of Johnson and Johnson's Spravato (esketamine nasal spray) as a monotherapy option for treatment resistant depression
Ticker: JNJ
Executed On: Aug 21, 2024 at 11:00 AM EDT
A Third View: Delving into the Phase 2 DAHLIAS clinical trial of Nipocalimab in patients with Sjögren's disease.
Ticker: JNJ
Executed On: Jul 31, 2024 at 05:30 PM EDT
A Second Look: Discussing the potential of Johnson and Johnson's Spravato (esketamine nasal spray) as a monotherapy option for treatment resistant depression
Ticker: JNJ
Executed On: Jul 31, 2024 at 02:15 PM EDT
Discussing the potential of Johnson and Johnson's Spravato (esketamine nasal spray) as a monotherapy option for treatment resistant depression
Ticker: JNJ
Executed On: Jul 31, 2024 at 10:00 AM EDT
A Second View: Delving into the Phase 2 DAHLIAS clinical trial of Nipocalimab in patients with Sjögren's disease.
Ticker: JNJ
Executed On: Jul 29, 2024 at 01:00 PM EDT
Delving into the Phase 2 DAHLIAS clinical trial of Nipocalimab in patients with Sjögren's disease.
Ticker: JNJ
Executed On: Jul 25, 2024 at 06:30 PM EDT
A Third View: Delving into the Phase 3 Vivacity-MG3 clinical trial on Nipocalimab, a monoclonal antibody being developed by Johnson & Johnson for the treatment of myasthenia gravis.
Ticker: JNJ
Executed On: Jul 10, 2024 at 05:15 PM EDT
A Second View: Delving into the Phase 3 Vivacity-MG3 clinical trial on Nipocalimab, a monoclonal antibody being developed by Johnson & Johnson for the treatment of myasthenia gravis.
Ticker: JNJ
Executed On: Jul 09, 2024 at 12:00 PM EDT
A Third Look: Reviewing the standard of care for MDD and the potential of JNJs Seltorexant
Ticker: JNJ
Executed On: Jul 03, 2024 at 04:30 PM EDT
Delving into the Phase 3 Vivacity-MG3 clinical trial on Nipocalimab, a monoclonal antibody being developed by Johnson & Johnson for the treatment of myasthenia gravis.
Ticker: JNJ
Executed On: Jul 03, 2024 at 09:30 AM EDT
A Third Look: Speaking with a physician on his experience using Pulsed Field Ablation
Tickers: BSX, JNJ, MDT, ABT
Executed On: Jun 13, 2024 at 05:30 PM EDT
A Second Look: Reviewing the standard of care for MDD and the potential of JNJs Seltorexant
Ticker: JNJ
Executed On: Jun 13, 2024 at 02:00 PM EDT
A Second Look: Speaking with a physician on his experience using Pulsed Field Ablation
Tickers: BSX, JNJ, MDT, ABT
Executed On: Jun 12, 2024 at 08:00 AM EDT
Speaking with a physician on his experience using Pulsed Field Ablation
Tickers: BSX, JNJ, MDT, ABT
Executed On: Jun 06, 2024 at 01:00 PM EDT
Reviewing the standard of care for MDD and the potential of JNJs Seltorexant
Ticker: JNJ
Executed On: Jun 05, 2024 at 10:00 AM EDT
A Third Opinion: Discussing the recent approval of JNJs Opsynvi for the treatment of Pulmonary Arterial Hypertension.
Ticker: JNJ
Executed On: May 23, 2024 at 12:00 PM EDT
A Second Opinion: Discussing the recent approval of JNJs Opsynvi for the treatment of Pulmonary Arterial Hypertension
Ticker: JNJ
Executed On: May 10, 2024 at 09:00 AM EDT
Discussing the recent approval of JNJs Opsynvi for the treatment of Pulmonary Arterial Hypertension
Ticker: JNJ
Executed On: Apr 03, 2024 at 05:00 PM EDT
Expanding on the recent approval of Rybrevant (amivantamab-vmjw) a first line treatment for lung cancer developed by Johnson & Johnson.
Ticker: JNJ
Executed On: Apr 03, 2024 at 03:00 PM EDT
A third look: Discussing TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Ticker: JNJ
Executed On: Mar 29, 2024 at 03:00 PM EDT
A Third Look: Discussing the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of Sjögren's syndrome along with the positive topline results from the Phase 2 DAHLIAS study
Ticker: JNJ
Executed On: Mar 20, 2024 at 11:00 AM EDT
A Third View: Investigating the results from the phase 2b FRONTIER clinical trial of JNJ-2113 in plaque psoriasis.
Ticker: JNJ
Executed On: Mar 15, 2024 at 02:00 PM EDT
A Second View: Investigating the results from the phase 2b FRONTIER clinical trial of JNJ-2113 in plaque psoriasis.
Ticker: JNJ
Executed On: Mar 15, 2024 at 01:00 PM EDT
A Third Opinion: A fresh look discussing the future usage of Pulsed Field Ablation for AFib procedures and looking at the newest data from JNJs Varipulse system
Tickers: JNJ, MDT, ABT, BSX
Executed On: Mar 15, 2024 at 11:00 AM EDT
Investigating the results from the phase 2b FRONTIER clinical trial of JNJ-2113 in plaque psoriasis.
Ticker: JNJ
Executed On: Mar 15, 2024 at 09:15 AM EDT
A Second Opinion: A fresh look discussing the future usage of Pulsed Field Ablation for AFib procedures and looking at the newest data from JNJs Varipulse system
Tickers: JNJ, MDT, ABT, BSX
Executed On: Mar 14, 2024 at 11:30 AM EDT
A Third Look: Discussing the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of myasthenia gravis along with the positive topline results from the Phase 3 VIVACITY study
Ticker: JNJ
Executed On: Mar 13, 2024 at 02:00 PM EDT
A look at the updated safety, efficacy and PK data from the on-going APEX-01 trial of ARX517 in patients with mCRPC.
Tickers: JNJ, AMAM
Executed On: Mar 12, 2024 at 05:40 PM EDT
A Second Look: Discussing the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of myasthenia gravis along with the positive topline results from the Phase 3 VIVACITY study
Ticker: JNJ
Executed On: Mar 11, 2024 at 05:30 PM EDT
A fresh look discussing the future usage of Pulsed Field Ablation for AFib procedures and looking at the newest data from JNJs Varipulse system
Tickers: JNJ, MDT, ABT, BSX
Executed On: Mar 05, 2024 at 05:00 PM EST
A second look: Discussing TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Ticker: JNJ
Executed On: Mar 01, 2024 at 02:00 PM EST
Discussing TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Ticker: JNJ
Executed On: Feb 29, 2024 at 04:00 PM EST
Discussing the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of myasthenia gravis along with the positive topline results from the Phase 3 VIVACITY study
Ticker: JNJ
Executed On: Feb 22, 2024 at 11:00 AM EST
A Third Look: Discussing the black box label added to Carvykti and concerns regarding T-cell malignancies in patients following treatment with BCMA- or CD19-directed CAR-T immunotherapies
Ticker: JNJ
Executed On: Feb 14, 2024 at 01:45 PM EST
A Third Look: Discussing the recent approval of Medtronic's PulseSelect pulsed field ablation catheter and Boston Scientific Farapulse system for use in patients with atrial fibrillation
Tickers: MDT, JNJ, ABT, BSX
Executed On: Feb 14, 2024 at 10:00 AM EST
Discussing therapeutics for MDD/TRD with a focus on psilocybin based therapies - 2nd look
Tickers: CMPS, XENE, NMRA, JNJ
Executed On: Feb 09, 2024 at 02:00 PM EST
A Second Look: Discussing the recent approval of Medtronic's PulseSelect pulsed field ablation catheter and Boston Scientific Farapulse system for use in patients with atrial fibrillation
Tickers: MDT, JNJ, ABT, BSX
Executed On: Feb 09, 2024 at 09:30 AM EST
A Second Look: Discussing the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of Sjögren's syndrome along with the positive topline results from the Phase 2 DAHLIAS study
Ticker: JNJ
Executed On: Feb 08, 2024 at 11:45 AM EST
Discussing the treatment landscape and the potential of nipocalimab, an investigational drug for the treatment of Sjögren's syndrome along with the positive topline results from the Phase 2 DAHLIAS study
Ticker: JNJ
Executed On: Feb 07, 2024 at 11:00 AM EST
A Third Look: Discussing the standard of care and the potential of Janssen Pharma's TREMFYA along with the VISIBLE Phase 3b Study of TREMFYA® (Guselkumab) in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
Ticker: JNJ
Executed On: Feb 05, 2024 at 03:00 PM EST
A Second Look: Discussing the standard of care and the potential of Janssen Pharma's TREMFYA along with the VISIBLE Phase 3b Study of TREMFYA® (Guselkumab) in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
Ticker: JNJ
Executed On: Feb 05, 2024 at 12:15 PM EST
Discussing therapeutics for MDD/TRD with a focus on psilocybin based therapies
Tickers: CMPS, XENE, NMRA, JNJ
Executed On: Feb 01, 2024 at 03:00 PM EST
Discussing the standard of care and the potential of Janssen Pharma's TREMFYA along with the VISIBLE Phase 3b Study of TREMFYA® (Guselkumab) in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
Ticker: JNJ
Executed On: Jan 30, 2024 at 07:00 PM EST
A Second Look: Discussing the black box label added to Carvykti and concerns regarding T-cell malignancies in patients following treatment with BCMA- or CD19-directed CAR-T immunotherapies
Ticker: JNJ
Executed On: Jan 09, 2024 at 01:00 PM EST
Discussing the black box label added to Carvykti and concerns regarding T-cell malignancies in patients following treatment with BCMA- or CD19-directed CAR-T immunotherapies
Ticker: JNJ
Executed On: Jan 08, 2024 at 02:00 PM EST
Discussing the recent approval of Medtronic's PulseSelect pulsed field ablation catheter for use in patients with atrial fibrillation
Tickers: MDT, JNJ, ABT, BSX
Executed On: Dec 20, 2023 at 11:00 AM EST
A Third Look: Discussing the potential of JNJ-1802, a first-in-class oral antiviral in development by Johnson & Johnson for the prevention of dengue fever.
Ticker: JNJ
Executed On: Dec 06, 2023 at 11:00 AM EST
A Second Look: Discussing the potential of JNJ-1802, a first-in-class oral antiviral in development by Johnson & Johnson for the prevention of dengue fever.
Ticker: JNJ
Executed On: Dec 06, 2023 at 10:00 AM EST
Discussing the potential of JNJ-1802, a first-in-class oral antiviral in development by Johnson & Johnson for the prevention of dengue fever.
Ticker: JNJ
Executed On: Nov 29, 2023 at 02:00 PM EST
Looking at the future use of Ketamine-based products for the treatment of patients with depression and schizophrenia
Tickers: JNJ, IBB
Executed On: Nov 20, 2023 at 04:35 PM EST
A Second Opinion: Examining the JNJ Phase 3 MARIPOSA, MARIPOSA-2 and PAPILLON study for RYBREVANT (amivantamab-vmjw) in EGFR-mutated lung cancer and the positive data for progression-free survival endpoints.
Ticker: JNJ
Executed On: Oct 31, 2023 at 06:00 PM EDT
Examining the JNJ Phase 3 MARIPOSA, MARIPOSA-2 and PAPILLON study for RYBREVANT (amivantamab-vmjw) in EGFR-mutated lung cancer and the positive data for progression-free survival endpoints.
Ticker: JNJ
Executed On: Oct 24, 2023 at 04:00 PM EDT
A Second View: Discussing the potential of an E. coli vaccine
Tickers: SNY, JNJ
Executed On: Oct 20, 2023 at 12:30 PM EDT
A Second view: Discussing the potential of Pulse field ablation for patients with AFib and the recent results of Boston Scientific's Farapulse system in the Advent trial
Tickers: BSX, MDT, JNJ, ABT
Executed On: Oct 20, 2023 at 10:00 AM EDT
Discussing the potential of Pulse field ablation for patients with AFib and the recent results of Boston Scientific's Farapulse system in the Advent trial
Tickers: BSX, MDT, JNJ, ABT
Executed On: Oct 13, 2023 at 05:15 PM EDT
Discussing the potential of an E. coli vaccine
Tickers: SNY, JNJ
Executed On: Oct 12, 2023 at 11:30 AM EDT
A Third Opinion: Discussing the Phase 3 SEQUENCE clinical trial of SKYRIZI versus STELARA for the treatment of Crohn's Disease.
Tickers: ABBV, JNJ
Executed On: Sep 27, 2023 at 03:00 PM EDT
A Second Opinion: Discussing the Phase 3 SEQUENCE clinical trial of SKYRIZI versus STELARA for the treatment of Crohn's Disease.
Tickers: ABBV, JNJ
Executed On: Sep 21, 2023 at 04:45 AM EDT
Discussing the Phase 3 SEQUENCE clinical trial of SKYRIZI versus STELARA for the treatment of Crohn's Disease.
Tickers: ABBV, JNJ
Executed On: Sep 20, 2023 at 05:00 PM EDT
A Third View: Looking into the potential of Tremfya (guselkumab) in patients with inflammatory bowel disease and moderate to severe active ulcerative colitis
Ticker: JNJ
Executed On: Sep 15, 2023 at 09:00 AM EDT
A Second View: Looking into the potential of Tremfya (guselkumab) in patients with inflammatory bowel disease and moderate to severe active ulcerative colitis
Ticker: JNJ
Executed On: Sep 14, 2023 at 04:30 PM EDT
Looking into the potential of Tremfya (guselkumab) in patients with inflammatory bowel disease and moderate to severe active ulcerative colitis
Ticker: JNJ
Executed On: Aug 30, 2023 at 12:30 PM EDT
A Second Opinion: Discussing the potential of AKEEGA (Niraparib and Abiraterone Acetate) from Johnson & Johnson recently approved by the FDA for the treatment of patients with Prostate Cancer
Ticker: JNJ
Executed On: Aug 25, 2023 at 09:00 AM EDT
A Second Look: Discussing the potential of RYBREVANT (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
Ticker: JNJ
Executed On: Aug 17, 2023 at 05:15 PM EDT
A Second Look: Discussing the standard of care of bladder cancer and the potential of Johnson & Johnson's TAR-200 "The preztel" and cetrelimab, a PD-1 inhibitor.
Ticker: JNJ
Executed On: Aug 16, 2023 at 03:00 PM EDT
Discussing the potential of AKEEGA (Niraparib and Abiraterone Acetate) from Johnson & Johnson recently approved by the FDA for the treatment of patients with Prostate Cancer
Ticker: JNJ
Executed On: Aug 15, 2023 at 08:00 AM EDT
Discussing the standard of care of bladder cancer and the potential of Johnson & Johnson's TAR-200 "The preztel" and cetrelimab, a PD-1 inhibitor.
Ticker: JNJ
Executed On: Aug 10, 2023 at 01:30 PM EDT
Discussing the potential of RYBREVANT (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Ticker: JNJ
Executed On: Aug 08, 2023 at 12:00 PM EDT
A Third Look: Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Tickers: JNJ, ABBV, BMY, AMGN, LLY
Executed On: Jul 20, 2023 at 04:00 PM EDT
A Second Look: Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Tickers: JNJ, LLY, AMGN, ABBV, BMY
Executed On: Jul 14, 2023 at 11:00 AM EDT
Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Ticker: JNJ
Executed On: Jul 12, 2023 at 05:30 PM EDT
Discussing the use of CARVYKTI(ciltacabtagene autoleucel) in multiple myeloma as early as the first line and the results of the Phase 3 CARTITUDE-4 study presented at ASCO.
Ticker: JNJ
Executed On: Jun 20, 2023 at 12:00 PM EDT
Discussing the potential and standard of care of Janssen's BALVERSA (erdafitinib) for the treatment of urothelial carcinoma based on the data that was recently presented at ASCO 2023
Ticker: JNJ
Executed On: Jun 14, 2023 at 01:00 PM EDT
Examining the current treatment landscape and Phase 3 A DUE study of the single tablet combination therapy of Macitentan and Tadalafil for the treatment of Pulmonary Arterial Hypertension (PAH) by Janssen Pharmaceuticals.
Ticker: JNJ
Executed On: Jun 02, 2023 at 09:30 AM EDT
A second look at the potential use of Nipocalimab currently being evaluated to treat patients at risk for HDFN in the UNITY clinical trial by Janssen Pharmaceuticals
Ticker: JNJ
Executed On: Mar 07, 2023 at 11:00 AM EST
A look at the potential use of Nipocalimab currently being evaluated to treat patients at risk for HDFN in the UNITY clinical trial by Janssen Pharmaceuticals
Ticker: JNJ
Executed On: Mar 03, 2023 at 09:00 AM EST
A look at Addex Therapeutics' ADX71149/JNJ-40411813 in combination with Levetiracetam or Brivaracetam in patients with Epilepsy
Tickers: ADXN, JNJ
Executed On: Feb 27, 2023 at 05:00 PM EST
A third discussion on the use of Spravato (esketamine nasal spray) with a prescriber
Ticker: JNJ
Executed On: Feb 16, 2023 at 10:00 AM EST
A second discussion on the use of Spravato (esketamine nasal spray) with a prescriber
Ticker: JNJ
Executed On: Feb 15, 2023 at 10:00 AM EST
Discussing the use of Spravato (esketamine nasal spray) with a prescriber
Ticker: JNJ
Executed On: Feb 13, 2023 at 04:00 PM EST
A second look: Discussing the potential of Talquetamab(GPRC5DxCD3) and the results from the Phase 1/2 MonumenTAL-1 study in patients with multiple myeloma highlighted at ASH 2022
Ticker: JNJ
Executed On: Dec 16, 2022 at 08:00 AM EST
Discuss the potential of Talquetamab(GPRC5DxCD3) and the results from the Phase 1/2 MonumenTAL-1 study in patients with multiple myeloma highlighted at ASH 2022
Ticker: JNJ
Executed On: Dec 14, 2022 at 02:00 PM EST
A Third View: Examining the potential of J&J's Tecvayli (teclistamab), in light of the recent FDA Approval for treatment of Multiple Myeloma
Ticker: JNJ
Executed On: Nov 22, 2022 at 04:30 PM EST
A Second View: Examining the potential of J&J's Tecvayli (teclistamab), in light of the recent FDA Approval for treatment of Multiple Myeloma
Ticker: JNJ
Executed On: Nov 09, 2022 at 11:20 AM EST
A third discussion of the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Tickers: OCGN, PFE, MRNA, JNJ
Executed On: Nov 09, 2022 at 11:00 AM EST
Examining the potential of J&J's Tecvayli (teclistamab), in light of the recent FDA Approval for treatment of Multiple Myeloma
Ticker: JNJ
Executed On: Nov 01, 2022 at 10:00 AM EDT
A second look at the standard of care for chronic graft-versus-host disease and the future use of ibrutinib and ruxolitinib in the pediatric population
Tickers: INCY, ABBV, JNJ, SNY
Executed On: Oct 28, 2022 at 10:30 AM EDT
A second discussion of the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Tickers: OCGN, PFE, MRNA, JNJ
Executed On: Oct 27, 2022 at 11:30 AM EDT
A look at the standard of care for chronic graft-versus-host disease and the future use of ibrutinib and ruxolitinib in the pediatric population
Tickers: ABBV, JNJ, SNY, INCY
Executed On: Oct 26, 2022 at 12:00 PM EDT
A third look at the clinical landscape for prevention of major cardiovascular events, including an in depth discussion about the phase 2 data of Milvexian, a factor XIa inhibitor
Tickers: BMY, JNJ
Executed On: Sep 22, 2022 at 04:30 PM EDT
A second look at the clinical landscape for prevention of major cardiovascular events, including an in depth discussion about the phase 2 data of Milvexian, a factor XIa inhibitor
Tickers: BMY, JNJ
Executed On: Sep 15, 2022 at 07:00 PM EDT
Looking at the clinical landscape for prevention of major cardiovascular events, including an in depth discussion about the phase 2 data of Milvexian, an anticoagulation medication in development by Bristol Myers and Janssen Pharmaceuticals
Tickers: BMY, JNJ
Executed On: Sep 12, 2022 at 02:00 PM EDT
A third look at Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, as monotherapy for the treatment of MDD and its P2 data
Tickers: RLMD, JNJ, AXSM
Executed On: Aug 31, 2022 at 04:00 PM EDT
A second look at Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, as monotherapy for the treatment of MDD and its P2 data
Tickers: RLMD, JNJ, AXSM, SAGE
Executed On: Aug 30, 2022 at 06:30 PM EDT
A look at the use and clinical efficacy of Hyaluronic acid for patients with osteoarthritis and the current treatment landscape
Tickers: JNJ, BVS, PCRX
Executed On: Aug 30, 2022 at 04:30 PM EDT
A look at the use of ELIQUIS, Xarelto, and other blood thinners for cardiovascular disease and atrial fibrillation
Tickers: BMY, JNJ, BAYN.XSWX
Executed On: Aug 26, 2022 at 01:30 PM EDT
A look at the potential of new CAR-T cell therapies in development for multiple myeloma
Tickers: ACLX, GRCL, OriCell Therapeutics, JNJ, LEGN, TSVT
Executed On: Jul 14, 2022 at 08:00 AM EDT
A Second Opinion: Discussing esketamine and psilocybin and their relevance in treating patients with Treatment-Resistant Depression
Tickers: JNJ, CMPS
Executed On: May 05, 2022 at 11:30 AM EDT
Discussing esketamine and psilocybin and their relevance in treating patients with Treatment-Resistant Depression
Tickers: JNJ, CMPS
Executed On: Apr 12, 2022 at 11:00 AM EDT
Discussion on BCMA targeted therapies in multiple myeloma - second look
Tickers: LEGN, TSVT, BMY, JNJ
Executed On: Feb 23, 2022 at 07:00 PM EST
A look at upcoming Cilta-cel PDUFA and other BCMA directed therapies
Tickers: LEGN, BMY, TSVT, JNJ
Executed On: Feb 17, 2022 at 03:00 PM EST

Upcoming & Overdue Catalysts (JNJ)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (JNJ)

Don’t see a strategic initiative related to the company you care about? Create your own!